Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter Drug Formulary Coverage Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy AMB25-AHS-C-00023-MO

    Ambetter Prescription Drug Formulary — Coverage Criteria

    Customize your policy alerts

    Sign up for Centene Policy AMB25-AHS-C-00023-MO alerts

    Get alerted when Policy AMB25-AHS-C-00023-MO changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the Ambetter prescription drug formulary tiers, coverage notes (prior authorization, step therapy, quantity and age limits), specialty pharmacy handling, and opioid fill limits for members under this plan.

    Policy Summary
    PayerCentene
    PolicyAmbetter Prescription Drug Formulary — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-MO
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionProviders must submit the Prior Authorization form and supporting documentation when PA is required for listed drugs to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Tier 0–4Formulary copay tiers described
    7-dayOpioid new‑start limits
    24/72hPA response times
    SpecialtySpecialty pharmacy requirement
    QL/ALQuantity/age limits present
    ~20+Distinct entries in extract

    Formulary Coverage Criteria

    Formulary coverage criteria

    Formulary coverage and restrictions are defined by tiers and per-product limits/requirements

    Formulary coverage basics: Drugs listed on the formulary are covered under the prescription drug benefit subject to tier placement; generics are preferred when available; tiers (Tier 0, 1A, 1B, 2, 3, 4) determine copayment and handling

    See Drug List Key for tier definitions

    Utilization management types: Coverage of individual products may be restricted by one or more of: Prior Authorization (PA), Step Therapy (ST), Quantity Limits (QL), Age Limits (AL), Specialty Pharmacy routing (SP), or max-fill/package intervals as shown on product rows

    Flags (PA/ST/QL/AL/SP) appear inline on formulary rows

    Opioid new-start restriction: New opioid starts are limited to a 7‑day supply; allowance up to two 7‑day fills during any 28‑day period and up to 28 non‑consecutive days in any 90‑day period; claims exceeding these limits require prior authorization
    Policy Summary
    PayerCentene
    PolicyAmbetter Prescription Drug Formulary — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-MO
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionProviders must submit the Prior Authorization form and supporting documentation when PA is required for listed drugs to avoid claim denial.
    SourceLink
    On This Page
    Formulary Coverage CriteriaFormulary Coding, Flags and LimitsPrior Authorization, Step Therapy and DocumentationTerms and AbbreviationsInitial Therapy and Starter Fill ControlsStep Therapy Rules and Affected ProductsQuantity and Age Limits by ProductSpecialty Pharmacy, Infusion and Site-of-Care NotesPolicy Background
    7 day initial supply; up to two 7‑day fills per 28 days; up to 28 days per 90 days

    Applies across opioid product entries

    Coverage conditions for adalimumab products (formulary entries)

    Formulary listing shows coverage with quantity limits and prior authorization for multiple adalimumab biosimilars and starter kits when conditions below are met:

    Adalimumab product coverage: Requested adalimumab product is listed on the formulary and within the applicable tier; product-level quantity limits apply (common daily-equivalent QL(0.143 EA daily)) and many presentations require prior authorization (PA)QL(0.143 EA daily) and package limits such as 1 max fill per 180 days for starter kits

    Starter kits and certain package presentations limited to 1 fill per 180 days; PA required as indicated on line items

    Coverage conditions for specialty injectables

    Specialty injectables (e.g., ARIKAYCE, ACTEMRA) are listed with PA and QL restrictions.

    Specialty injectable coverage: Coverage for listed specialty injectable products requires prior authorization when indicated and fulfillment may be routed via specialty pharmacy (SP); product entries include specific quantity limits (e.g., ACTEMRA ACTPEN QL(3.6 mL per 28 days retail; 4 mL per 28 days mail))various QL per 28‑ or 180‑day intervals as shown per product

    Site-of-care/SP handling may be required for some antineoplastics and specialty biologics

    Coverage for PDE4 inhibitor (OTEZLA)

    OTEZLA entries include age limits, quantity limits, and PA.

    OTEZLA coverage: Coverage of OTEZLA (apremilast) requires prior authorization; certain presentations include an age limit (AL) and quantity limits (QL) — example: AL(At least 45 yrs old Up to 79 yrs old) and QL(2 EA daily)Age >=45 and <=79 for specified entries; QL(2 EA daily)

    Starter/package presentations may also have max‑fill per 180 days and PA flags

    Step therapy/first-line requirement for certain ACTEMRA entries

    Some ACTEMRA formulations note a drug trial requirement.

    NSAID trial prior to coverage: Coverage of a specified ACTEMRA presentation requires documentation of a prior trial of ibuprofen ('Must try ibuprofen') before coverage is approvedTrial of ibuprofen documented

    The formulary line does not specify duration or failure criteria; document trial in PA request

    Formulary coverage controls (partial)

    Coverage and utilization controls observed in this segment (examples follow):

    New start opioid supply restriction: For many opioid products listed, new starts are limited to a 7‑day supply7 day

    Appears repeatedly across hydromorphone, meperidine, methadone, morphine, acetaminophen‑codeine, hydrocodone combinations

    Quantity limits: Specific formulations have per‑day or per‑fill quantity limits (QL) such as QL(6 EA daily), QL(1 EA daily), QL(0.146 mL), QL(100 mL daily), QL(3.2 GM)see product lines

    Limits vary by product and strength and are shown on each formulary row

    Prior authorization requirement: Certain formulations require prior authorization (PA) as noted in‑line (examples include ENBREL entries and select opioid or specialty formulations)PA required

    PA flags appear adjacent to specific entries and must be followed

    Tiered coverage: Products are assigned tiers (e.g., 1A,1B,2,3,4) which may affect member cost share and utilization pathways including ST or SP where indicatedtier listed

    Refer to tier on product row for preferred ordering and potential step requirements

    Formulary coverage summary (excerpt)

    Coverage and utilization management rules in this excerpt are conveyed by tier assignment, quantity limits, and PA indicators.

    Tiering and utilization controls: Drugs are assigned tiers (Tier 0–4) that determine formulary preference and member cost share; many entries include quantity limits (QL) and some include prior authorization (PA) or specialty (SP) indicators which must be satisfied for coverageObserve QL/AL/PA values on each product line

    Formulary is not exhaustive; consult full plan documents for benefit‑specific rules

    Formulary product lines (cardiovascular combinations)

    Coverage statements as formulary entries (tier, ILimits, PA noted where present).

    ACE inhibitor/hydrochlorothiazide combinations: Multiple ACE inhibitor + hydrochlorothiazide combination products are listed with tier assignments and product‑specific quantity limits (e.g., QL(1–4 EA daily) depending on product) and PA flags where shownsee per‑product QL values

    Tier placement may vary (1A/1B/3) across formulations

    Anti-infectives

    Anti-infective and antiprotozoal agents with tiers and limits.

    Anti‑infective coverage: Anti‑infective class entries include tier assignments and quantity limits (e.g., Anti‑infective Agents Misc. QL(4 EA daily; 40 EA per fill retail)); select products (XIFAXAN) include age limits and PA flagssee product rows (e.g., XIFAXAN 200 MG: 9 EA per 3 days; AL(>=12 yrs); PA)

    Some formulations require PA or have per‑course QLs

    Antimalarials - restricted use

    Antimalarial agents are flagged as 'Covered for malaria treatment only' with fill-frequency and quantity limits for several products.

    Antimalarial restricted coverage: Atovaquone‑proguanil and other antimalarials are covered only for malaria treatment and are subject to fill frequency and quantity restrictions (example: Limit 1 fill every 180 days; QL(12 EA per fill); 1 max fill per 180 days)1 max fill per 180 days; QL(12 EA per fill)

    PA may be required for some antimalarial combinations

    Chemotherapy agents (PA/SP controls)

    Antineoplastic agents and supportive oncology drugs with tiers, QL, SP and PA controls.

    Antineoplastic access controls: Coverage for chemotherapy and adjunctive oncology agents is subject to specialty handling (SP) and prior authorization (PA) where indicated; some agents have per‑day or per‑fill quantity limits (QL) documentedsee per‑drug QL/SP/PA entries (e.g., oxaliplatin QL(3 EA daily); many agents flagged SP; PA)

    Site-of-care and specialty routing may apply for multiple antineoplastic agents

    Covered with utilization controls

    Coverage for listed drugs is subject to utilization controls

    Standard utilization requirements: Drug coverage requires adherence to the formulary row indicators: follow the listed tier, obtain prior authorization when 'PA' is shown, route via specialty pharmacy when 'SP' is shown, observe step therapy flags (ST), and do not exceed quantity limits (QL)see per‑product ILimits

    Medical necessity and full clinical criteria (if any) are maintained in separate authorization policies

    Formulary product coverage (partial)

    Formulary coverage entries and utilization rules (partial list) — each product entry includes tier, limits, and utilization management indicators.

    Topical/dermatologic controls (sample): Topical dermatologic products commonly include age limits (e.g., AL(At least 12 yrs old)), per‑day or per‑fill quantity limits (QL values such as 3 GM daily, 15 GM per 30 days), and may require PA or ST as indicatedAL(>=12 yrs) and product‑specific QL values

    Examples include clindamycin phosphate combinations, tretinoin, calcipotriene‑betamethasone lines

    General PA requirement for non‑FDA uses

    Coverage and authorization notes present in excerpt

    PA for non‑FDA uses: Non‑FDA approved uses of listed products require prior authorization as noted; coverage for off‑label uses is contingent on PA and supporting documentationPA required for non‑FDA uses

    Appears for multiple topical, diagnostic and other product groups

    The Formulary lists FDA‑approved brand and generic medications covered under the prescription drug benefit and indicates that generics are preferred when available. It is intended as a coverage guide; generics should be considered first‑line where available, and preferred brand drugs are identified for situations where a generic is not suitable.

    The extract reviewed does not include any explicit clinical exclusion or ineligibility conditions (e.g., specific diagnoses or patient populations that are categorically excluded) within the cited formulary lines. Coverage statements in this segment focus on tiering, quantity limits (QL), age limits (AL), and prior authorization (PA) flags rather than listing clinical exclusions.

    Non‑FDA‑approved uses of several topical and diagnostic products require prior authorization. When an item is noted as requiring PA for non‑FDA uses, providers must submit supporting documentation of medical necessity per the payer's prior authorization process before those uses will be considered for coverage.

    The reviewed segments do not contain explicit statements labeling any product or formulation as 'Not Medically Necessary.' Formulary lines in these chunks instead record coverage attributes such as tier assignment, QL/AL values, and PA or ST flags; absence of an explicit NMN designation in these extracts does not imply NMN language is not present elsewhere in the full policy.

    Within the examined extract there are no explicit 'not medically necessary' determinations applied to specific products. Coverage information is conveyed through utilization controls (e.g., PA, QL, AL, ST) rather than explicit NMN statements in these chunks.

    This segment does not include explicit 'Not Medically Necessary' (NMN) language for the products shown. Formulary entries here emphasize quantity limits and tier placement without introducing NMN findings in the cited lines.

    Formulary Coding, Flags and Limits

    Formulary drug row annotations (QL, AL, PA, ST, SP)mixed
    QL(2 EA daily)Quantity limit examples as shown in drug rows
    AL(At least 6 yrs old)Age limit examples as shown in drug rows
    PAPrior authorization required as listed in drug rows
    STStep therapy indicator in drug rows
    SPSpecialty tier indicator
    No CPT/HCPCS/ICD/NDC codes presentmixed
    No codes listed
    Formulary drug entries and special-formulation codesmixed
    OTEZLA TABSOtezla tablets — ILimits QL(2 EA daily); PA; age limits noted
    ENBREL SURECLICKEnbrel SureClick — ILimits QL(.146 ML daily); PA
    ENBREL SOSY 50 MG/MLEnbrel 50 mg/mL syringe — ILimits QL(0.286 ML daily); SP; PA
    butalbital-acetaminophen-caffeine CAPS 40 MG-50 MG-325 MGButalbital-containing combination capsules — tiers and QL vary; some require PA
    hydromorphone hcl SOLN IJ 10 MG/MLHydromorphone solution — New starts limited to 7 day supply; QL(100 ML daily)
    hydromorphone hcl TABSHydromorphone tablets — New starts limited to 7 day supply; QL noted
    meperidine hcl SOLN IJ 100 MG/MLMeperidine solution — PA; New starts limited to 7 day
    methadone hcl SOLN PO 5 MG/MLMethadone oral solution — QL(100 ML daily) or other daily QL; PA noted
    morphine sulfate CP24Morphine sulfate controlled-release — New starts limited to 7 day supply; QL limits
    acetaminophen w/ codeine TABS 15 MG-300 MGAcetaminophen/codeine tablets — New starts limited to 7 day supply; QL values vary
    1–10 of 15
    1/2
    Formulary entries (no procedure codes)mixed
    no CPT/HCPCS presentThis extract contains drug names, tiers and limits but no procedure or billing codes were listed in these chunks.
    Formulary product entries (partial)NDC|drug_name_mapped
    XARELTO TABS 15 MGrivaroxaban — Tier and QL entries present
    enoxaparin sodium 300 MG/3MLenoxaparin formulations with QL and PA flags
    fondaparinux sodium 2.5 MG/0.5MLfondaparinux with QL and tier entries
    NAYZILAMnasal midazolam — listed with QL and PA
    VALTOCO 15 MG/DOSEdiazepam/lorazepam analogs listed with QL
    DIACOMIT PACK 250 MG / 500 MGstiripentol products listed with QL
    BRIVIACT SOLN PO 10 MG/MLbrivaracetam solution with QL; PA
    BANZEL TABS 200 MG / 400 MGrufinamide with QL; PA
    vigabatrin PACK / TABSvigabatrin with QL; SP; PA
    SPRAVATO (56 MG/84 MG DOSE)esketamine nasal — listed with PA and tier info
    1–10 of 11
    1/2
    Formulary product referencesNDC|brand
    XIFAXAN 200 MGrifaximin 200 mg (product line referenced with AL and PA constraints)
    XIFAXAN 550 MGrifaximin 550 mg (product line referenced with QL and PA)
    Antineoplastic agentsbrand|generic
    cisplatin SOLN 100cisplatin solution 100 (tier 4; ILimits = SP; PA)
    busulfan SOLNbusulfan solution (ILimits = SP; PA)
    melphalan hcl IVmelphalan hcl IV (tier 1B; listed)
    Utilization control codes and indicatorsmixed
    QL(1 EA daily)Quantity limit example shown for several agents
    QL(2 EA daily)Quantity limit example shown for several agents
    QL(0.143 EA daily)Quantity limit example shown for agents such as TRAZIMERA and GILOTRIF
    SPSpecialty Pharmacy indicator
    PAPrior Authorization indicator
    Formulary utilization codes (QL, AL, PA)mixed
    QL(8 EA daily)quantity limit example for entacapone
    QL(2 EA daily)quantity limit example for carbidopa-levodopa TABS
    QL(0.072 EA dailylPAquantity limit shown for PERSERIS PRSY (format from doc)
    AL(At least 18 yrs old)age limit example
    PAprior authorization flag
    Formulary flags and quantity limitsmixed
    QL(1.67 GM daily)quantity limit example for betamethasone valerate FOAM
    QL(8 ML daily)quantity limit example for betamethasone valerate OINT
    QL(4 GM daily)quantity limit example for calcipotriene-betamethasone dipropionate
    PAprior authorization flag (appears for multiple entries)
    STstep therapy flag (appears for multiple entries)
    QL(3 GM daily)quantity limit example for hydrocortisone butyrate OINT
    QL(15.15 GM daily)quantity limit example for hydrocortisone topical CREA/SOLN entries
    QL(2 GM daily)quantity limit example for clobetasol propionate GEL/CREA
    QL(3.5 GM daily)quantity limit example for halobetasol propionate
    QL(0.082 ML daily)small-volume QL noted for some DUPIXENT-mapped entries
    1–10 of 13
    1/2
    inv-35: Opioid new-start limits — new starts limited to 7-day supply with allowed fills in 28/90-day windows
    New-start restrictionNew opioid starts limited to a 7-day supply; providers may submit PA for fills exceeding limits
    28-day window allowanceAllow up to two 7-day fills during any 28-day period
    90-day window allowanceAllow up to a total of 28 non-consecutive days supply in any 90-day period (applies cumulatively across opioids)
    Denial riskFills exceeding the new-start allowance may be denied without prior authorization or justification
    inv-36: Package max-fill interval — e.g., 1 max fill per 180 days for starter kits
    Package max-fill intervalStarter kits / certain package presentations limited to 1 max fill per 180 day(s)
    Applies toAdalimumab starter kits and some package presentations noted as 'package(s) per 180 day(s)'
    DocumentationDocumentation supporting package/dispense limits should be provided on PA requests
    inv-37: Adalimumab daily-equivalent QL — QL(0.143 EA daily) example
    Adalimumab daily-equivalent QLQL(0.143 EA daily)
    Package limits also notedMany adalimumab entries also include package limits per 180 day(s) and PA
    Applies to multiple variantsQL(0.143 EA daily) repeated across biosimilars, pens, syringes and starter kits
    inv-38: OTEZLA age limit — At least 45 yrs old up to 79 yrs old
    Age range for OTEZLAAL(At least 45 yrs old Up to 79 yrs old)
    Quantity/authorizationOTEZLA TABS: ILimits include QL(2 EA daily) and PA noted on entries
    Package presentationOTEZLA TBPK entries include package-per-180-day limits and PA on some rows
    inv-39: New-start supply limit — 7 day new-start supply examples
    New-start supply examplesNew starts limited to a 7-day supply (applies to many opioid formulations) — initial fills constrained to 7 days
    Product examplesHydromorphone, meperidine, methadone, morphine and certain combination products list 'New starts limited to 7 day supply'
    PA option for excessProviders may submit Prior Authorization for fills exceeding the 7-day new-start limit
    inv-40: Quantity limits (examples) — assorted QL formats observed across document
    Assorted QL formats observedExamples observed: QL(2 EA daily); QL(6 EA daily); QL(0.146 ML daily); QL(100 ML daily); QL(3.2 GM); QL(5 package(s) per 30 day(s))
    Per-fill vs per-dayQLs are expressed per day (EA/ML/GM), per fill (EA per fill), or as max fills per period (e.g., per 180 days)
    Retail vs mail distinctionsSome entries specify different per-fill limits for retail vs mail (e.g., ondansetron 45 EA per fill retail; 45 per fill mail)
    inv-41: examples of quantity limits — sample QL values from entries
    Sample QL valuesExamples include QL(3 EA daily); QL(0.067 EA daily for granisetron IV); QL(0.25 ML daily and QL(0.0714 ML daily) for REPATHA variants
    Antifungals/antiviralsItraconazole/posaconazole entries show QL(20 ML daily) or QL(4 EA daily)
    Class-level QLsSome classes show aggregated limits (e.g., Anti-infective Agents Misc. QL(4 EA daily; 40 EA per fill retail))
    inv-42: Examples of QL thresholds — package and mL/EA thresholds
    QL threshold examplesExamples: 5 package(s) per 30 days; 60 mL daily; 1–10 EA per 30 days depending on product
    Max fills per periodSome injectables note '1 max fill per 180 day(s)' or '1 max fill per 90 day(s)' depending on product
    Dose-unit variabilityThresholds use EA, ML, GM, package(s) depending on formulation and route
    inv-43: Selected QL examples — assorted examples including 45 EA per fill
    Selected QL examplesExamples across entries include: 45 EA per fill; QL(3 EA daily); QL(4 EA daily); QL(20 ML daily); QL(0.143 EA daily)
    Starter-kit/package examplesCertain starter kits list package limits per 180 days in addition to daily EA-equivalents
    Biologic/ml examplesBiologic entries commonly use ML daily-equivalents (e.g., 0.143 EA daily equivalent mapping) for dosing limits
    inv-44: Anti-infective Agents Misc. QL — QL(4 EA daily; 40 EA per fill retail)
    Class-level anti-infective QLAnti-infective Agents Misc.: QL(4 EA daily; 40 EA per fill retail)
    XIFAXAN 200 mgXIFAXAN 200 MG: 9 EA per 3 day(s) retail; 9 EA per 3 days mail; AL(At least 12 yrs old); PA
    Atovaquone-proguanilAtovaquone-proguanil HCl: Limit 1 fill every 180 days; QL(12 EA per fill retail; 12 per fill mail)
    inv-45: XIFAXAN 200 MG limit — 9 EA per 3 day(s) retail; 9 EA per 3 days mail
    XIFAXAN 200 MG limit9 EA per 3 day(s) retail; 9 EA per 3 days mail; AL(At least 12 yrs old); PA
    XIFAXAN 550 MGXIFAXAN 550 MG: QL(3 EA) or QL(3 EA per course); PA noted
    Context noteThese limits are presented per course/fill and include age and PA annotations
    inv-46: Atovaquone-proguanil hcl fill limit — Limit 1 fill every 180 days; QL(12 EA per fill)
    Atovaquone-proguanil fill limitLimit 1 fill every 180 days; QL(12 EA per fill retail; 12 per fill mail); 1 max fill(s) per 180 day(s)
    Indication restrictionCovered for malaria treatment only (per entry) and PA may apply
    Retail/mail parityPer-fill QL specified for both retail and mail channels (12 EA per fill)
    inv-47: Quantity examples — assorted QL examples including 1 EA daily and 0.143 EA daily
    Common QL numeric examplesExamples include QL(1 EA daily), QL(2 EA daily), QL(0.143 EA daily)
    Route/format diversityQLs appear as EA/day, ML/day, GM/day, or per-fill counts depending on product form
    Oncology/biologic parallelsMany oncology and biologic agents use small daily ML/EA equivalents (e.g., 0.143 EA) for dosing limits
    inv-48: Minimum age — examples of AL values (6 yrs, 10 yrs, 18 yrs) as specified
    Minimum age examplesAge limits observed: At least 6 yrs old; At least 10 yrs old; At least 18 yrs old; At least 12 yrs old for many topical entries
    Topical age enforcementTopical acne/dermatologic products frequently include AL(At least 12 yrs old)
    Documentation requiredAge limitation must be documented on authorization requests when AL is specified

    Prior Authorization, Step Therapy and Documentation

    Prior Authorization

    Prior Authorization Submission, Timing and Required Documentation

    Prior Authorization (PA), Step Therapy (ST), Specialty (SP) flags and quantity/age/package limits are applied across the formulary. Providers must submit a completed Prior Authorization form and supporting documentation (clinical rationale, prior treatment history, age/weight information, and package/dispense justification) when PA is indicated. Urgent requests: response within 24 hours of receipt of all necessary information. Non‑urgent requests: response within 72 hours unless state law requires a faster response. Incomplete PA requests may be denied; a denial will explain missing information or clinical reasons.

    • Required information for PA: diagnosis, prior therapies tried (including step therapy attempts), member age/weight when relevant, requested dose/quantity and justification for package/starter kit limits, and NDC or product name as shown on formulary.
    Prior Authorization

    PA and Specialty Routing for Biologics, Injectables and Oncology Drugs

    Many high-cost biologics, specialty injectables, oncology agents, and some antivirals require prior authorization and/or specialty routing. PA is required for most adalimumab products and starter kits (package and 180‑day max‑fill limits apply); submit documentation supporting package limits and clinical indication. Antineoplastic agents frequently require both PA and enrollment in a specialty/site program (SP) before coverage; failure to obtain PA/SP can result in claim denial.

    • Adalimumab: PA and package/180‑day max fills apply to branded biosimilars and starter kits; documentation must support package/dispense limit and indication.
    • Specialty injectables (examples): ARIKAYCE, ACTEMRA, ENBREL, STELARA, benefits often require SP routing and PA.
    • Oncology agents: many agents (e.g., cisplatin, busulfan, carmustine, trastuzumab biosimilars) marked SP; PA required and program enrollment may be necessary.
    Documentation Required

    Formulary Flags, Age Limits and Inline PA/Step Indicators

    Formulary entries may show inline flags and limits that create operational PA or step edits. Examples include age limits (AL), quantity limits (QL), step therapy (ST), package or max‑fill per period, and explicit 'PA' next to formulations. Providers should verify the formulary line‑item for these flags and include those details in the PA request to avoid denials.

    • Age limits: OTEZLA and other agents have age or age‑range conditions noted on formulary lines; include member age in PA.
    • XIFAXAN: 200 mg (9 tablets/3 days) and 550 mg (3 tablets) formulations have Age Limit (AL) and PA noted; verify AL (e.g., 'At least 12 yrs old') when requesting PA.
    • Topical agents and other select formulations list PA or ST inline (e.g., clindamycin/benzoyl peroxide GEL, tretinoin microsphere) — include formulation and indication in requests.
    Billing Rule

    Quantity, Starter‑Supply and Package Limits

    Quantity limits, starter‑supply caps, package limits, and max fills are enforced. New starts for certain opioid and biologic products are limited (for example, 7‑day new‑start limits on many opioid preparations). Exceeding posted quantity/package limits may require PA and could lead to claim denial if not authorized.

    • Quantity limits (QL) shown on formulary lines must be supported in the PA request (e.g., per‑day or per‑period QL values).
    • Starter kits and package limits: many adalimumab starter kits and some specialty drugs limited to 1 package per 180 days; document clinical need for additional packages.
    • New starts: certain opioids and injectables limited to a 7‑day supply for new starts; requests for larger fills require PA.
    Prior Authorization

    Non‑FDA Uses and Coverage Exceptions

    Non‑FDA (off‑label) or non‑covered uses require prior authorization and clinical justification. Providers must include supporting evidence when requesting coverage for non‑FDA uses.

    • Non‑FDA uses: explicitly marked as requiring PA across multiple product groups (e.g., select diagnostic/enzyme products and topical agents).
    • Formulary entries marked 'NF' or notes indicating 'Non‑FDA approved uses require Prior Authorization' must be accompanied by clinical rationale and supporting literature.
    Step Therapy

    Step Therapy, Tiering and Required Evidence

    Step therapy (ST) and tier placement affect PA requirements. Some lines require trial of preferred agents first (for example, 'Must try ibuprofen' for certain anti‑inflammatory injectables); ST flags and tiers imply step edits though explicit step rules may be in a separate segment. When ST is indicated, document prior trials and outcomes.

    • Document prior medication trials and dates when ST is invoked (e.g., trial of ibuprofen before ACTEMRA formulations).
    • Tiering influences coverage and may trigger PA or step edits; include alternative therapies tried and reasons for failure or intolerance.

    Terms and Abbreviations

    inv-129: Formulary tiers and brief meanings (Tier 0–4)
    Tier definitions (summary)Tier 0–4: Tier 0 (no copay prevention drugs); Tier 1A/1B/1 (low copay); Tier 2 (medium copay preferred brands); Tier 3 (high copay/non-preferred); Tier 4 (specialty)
    Specialty channelSpecialty-tier drugs may require fulfillment at participating specialty or hemophilia network pharmacies
    Tier impacts cost/shareTier assignment indicates formulary preference and likely member cost share
    inv-130: Formulary abbreviations (PA, ST, QL, NF, SP, SF)
    Common abbreviationsPA = Prior Authorization; ST = Step Therapy; QL = Quantity Limit; NF = Non-formulary; SP = Specialty; SF = Split Fill
    Usage contextAbbreviations are shown inline next to product entries to indicate utilization controls
    ST meaningST indicates a required trial of preferred agents before coverage of another drug
    inv-131: QL definition — quantity limit example
    QL definitionQuantity Limit — maximum allowed units per specified time period (examples: '0.143 EA daily', '12 EA per fill', '1 max fill per 180 days')
    Formats observedFormats include per day (EA/ML/GM), per fill (EA per fill), and max fills per period (per 30/90/180 days)
    Applies at claim adjudicationSpecified QLs are enforced at dispensing and may trigger PA if exceeded
    inv-132: PA definition — prior authorization requires payer approval
    PA definitionPrior Authorization — requires payer approval prior to dispensing to be covered
    When usedPA appears inline next to many specialty, high-cost, or non-formulary products
    Provider actionProviders must submit the Prior Authorization form and supporting documentation when PA is indicated

    Initial Therapy and Starter Fill Controls

    Initial therapy controls

    Initial fill and supply controls

    Opioid new starts: New opioid prescriptions are limited to a 7‑day supply; up to two 7‑day fills allowed in any 28‑day period and up to 28 non‑consecutive days in any 90‑day period; fills beyond these limits require prior authorization7 day initial supply; up to two 7‑day fills per 28 days; up to 28 days per 90 days

    Providers should include justification when requesting coverage beyond initial limits

    Initial step requirement

    Formulary notes a required trial for at least one product group.

    Initial step requirement: Certain products require trial of a listed lower‑step agent before coverage (example: 'Must try ibuprofen' documented as required prior to coverage of a specified formulation)Documented trial of specified preferred agent

    Failure/duration criteria not provided in the extract; include trial evidence in PA request

    Initial therapy limits

    Initial dispensing constraints observed

    Initial opioid dispensing limits: For many opioid and opioid‑combination products, initial dispensing is limited to a 7‑day supply; some opioid rows also show product‑specific QL values that must be observed7 day initial supply

    Claims exceeding initial supply or QL may require PA or justification

    Topical acne/antibiotic initial coverage controls

    Formulary utilization controls for topical acne agents

    Topical acne/antibiotic controls: Coverage for topical acne and antibiotic products is subject to age limits (commonly AL(At least 12 yrs old)), quantity limits (QL per day or per fill), and may require prior authorization (PA) or step therapy (ST) as indicated on product rowsAL(>=12 yrs) and product QL values (e.g., QL(3 GM daily))

    Document patient age and prior treatments when submitting PA

    Initial topical therapy constraints (partial)

    Examples of initial use constraints appearing in the extract

    Age and quantity constraints for topicals: Many topical agents are limited to patients 'At least 12 yrs old' and have daily or per‑fill quantity limits (examples: QL(15 GM per 30 days), QL(6 GM daily), QL(4 ML daily)); some topical combinations include ST or PA flagsAL(>=12 yrs); product QL as listed

    Per‑product QL/AL values must be followed at dispensing and in PA documentation

    Step Therapy Rules and Affected Products

    ExamplePolicy note
    Lisdexamfetamine (capsules; chewable)Listed with ST (step therapy) indicating a required trial of preferred stimulant agent(s) before coverage of lisdexamfetamine.
    ExamplePolicy note
    Specified ACTEMRA formulation entries'Must try ibuprofen' is stated as a prerequisite trial prior to coverage for the listed formulation.
    ExamplePolicy note
    Butalbital-containing combination products (various capsules/tablet strengths)Appear in multiple tiers; some presentations include PA and differing QL entries, indicating tier placement may affect PA/step application.
    ExamplePolicy note
    Tier assignments across product linesTier designations (Tier 1A/1B/2/3/4) indicate preferred ordering; explicit step durations or number of required failures are not specified in the excerpt.
    ExamplePolicy note
    NAYZILAM (nasal midazolam) listingFormulary line shows QL and an 'ST' indicator on one entry, demonstrating presence of an ST flag on the product line.
    ExamplePolicy note
    Insulin sensitizing agents / higher-tier classesTiering combined with 'SP; PA' or similar flags implies required programmatic steps (e.g., specialty routing or prior authorization) before accessing higher-tier therapies.
    ExamplePolicy note
    Antihypertensive combination products (multiple combos listed)Several combination antihypertensives are labeled 'ST' in the formulary, showing ST flags applied to combination products.
    ExamplePolicy note
    Antineoplastic class entries (cisplatin, busulfan, others)Many antineoplastic entries include 'SP; PA' or 'PA' indicating controlled access pathways (specialty pharmacy/site-of-care and prior authorization) before coverage.
    ExamplePolicy note
    Apomorphine hydrochloride entryListed with QL and 'ST.' indicating a step therapy requirement for that agent/formulation.
    ExamplePolicy note
    Verapamil / pulmonary hypertension–related entries; treprostinil/digoxin linesEntries show 'PA' or 'SP; PA' flags, demonstrating that step or specialty program enrollment and prior authorization are used for some cardiovascular/pulmonary hypertension agents.
    ExamplePolicy note
    Topical combination acne/dermatologic agents (e.g., calcipotriene‑betamethasone dipropionate; clindamycin–benzoyl peroxide)Some topical combination products are flagged 'ST', indicating step therapy applies to topical combination agents shown in the formulary.
    ExamplePolicy note
    Topical formulations (clindamycin phosphate topical lines, tretinoin, adapalene, etc.)Multiple topical entries include 'ST' in the ILimits or indicate age/QL constraints, showing topical formulations may be subject to step therapy requirements.
    ExamplePolicy note
    Clobetasol propionate foam and gel formulationsClobetasol propionate FOAM and GEL lines include QL values and are annotated with 'ST', indicating step therapy flags on these topical corticosteroid formulations.
    ExamplePolicy note
    Higher-tier products and specialty/PA flagged agentsTier assignments and PA/SP markers indicate preferred agents at lower tiers; higher-tier agents frequently require prior authorization or stepping through preferred alternatives before coverage is allowed.

    Quantity and Age Limits by Product

    Specialty Pharmacy, Infusion and Site-of-Care Notes

    Note
    Note
    Note
    Note

    Policy Background

    The Formulary is a guide to FDA‑approved brand and generic medications covered under the prescription drug benefit; it is not a complete list. Not all dosage forms or strengths may be covered, and specific prescription benefit plan designs may exclude certain products or categories even if they appear in this document. Check the member's benefit plan for coverage limitations and member cost‑share.